Top

Cardiology and Therapy

Published in:

01-06-2021 | Autopsy | Review

Estimating the Gender Distribution of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis

Authors: Florint Kroi, Nils Fischer, Ana Gezin, Mahmoud Hashim, Mark Hermannes Rozenbaum

Published in: Cardiology and Therapy | Issue 1/2021

Abstract

Introduction

This study investigates the gender distribution in patients diagnosed with wild-type transthyretin amyloidosis cardiomyopathy (ATTRwt).

Methods

A systematic review and meta-analysis of the male proportion in diagnosed ATTRwt patients were conducted. To avoid overlapping population, pooled estimates in the primary analysis were based on all unique studies. In secondary analyses, we considered predefined subsets of studies based on study sample size, recruitment years, geography, study design, age at diagnosis, and method of diagnosis. Additional meta-regression analyses were tested for potential determinants of gender distribution.

Results

Twenty-eight unique studies (2542 patients) were included in the meta-analysis. Male proportion in patients with ATTRwt was 86.9% (95% confidence interval 81.5–91.6%). Studies, including patients older than 80 years at diagnosis, had a 29.1% (p value < 0.001) lower male proportion compared to studies, including younger patients. After adjusting for age, studies using autopsy as a method of diagnosis had a 21.1% (p value 0.002) lower male proportion compared to other studies.

Conclusions

Studies conducted to date suggest ATTRwt disproportionally affects males. The proportion of males was significantly impacted by the age at diagnosis and method diagnosis, which may suggest important gender-based differences in the clinical manifestation and diagnostic challenges of ATTRwt in females that warrant future research.

Available only for authorised users

Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7(7):398–408. https://doi.org/10.1038/nrcardio.2010.67 ([PMID: 20479782]).CrossRefPubMed

Mankad AK, Shah KB. Transthyretin cardiac amyloidosis. Curr Cardiol Rep. 2017;19(10):97. https://doi.org/10.1007/s11886-017-0911-5 ([PMID: 28840452]).CrossRefPubMed

Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286–300. https://doi.org/10.1161/circulationaha.111.078915 ([PMID: 22949539]).CrossRefPubMedPubMedCentral

Arvidsson S, Pilebro B, Westermark P, Lindqvist P, Suhr OB. Amyloid cardiomyopathy in hereditary transthyretin V30M amyloidosis—impact of sex and amyloid fibril composition. PLoS ONE. 2015. https://doi.org/10.1371/journal.pone.0143456 ([PMID: 26600306]).CrossRefPubMedPubMedCentral

Santos D, Coelho T, Alves-Ferreira M, et al. The hidden story behind gender differences in familial amyloid polyneuropathy (FAP) ATTRV30M. Orphanet J Rare Dis. 2015;10(Suppl 1):O4. https://doi.org/10.1186/1750-1172-10-S1-O4.CrossRefPubMedCentral

Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(7 Suppl):S107–12 ([PMID: 28978215]).PubMed

Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34(7):520–8. https://doi.org/10.1093/eurheartj/ehs123 ([PMID: 22745357]).CrossRefPubMed

Arbustini E, Merlini G. Early identification of transthyretin-related hereditary cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7(5):511–4. https://doi.org/10.1016/j.jcmg.2014.03.007 ([PMID: 24831211]).CrossRefPubMed

Rapezzi C, Lorenzini M, Longhi S, et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev. 2015;20(2):117–24. https://doi.org/10.1007/s10741-015-9480-0 ([PMID: 25758359]).CrossRefPubMed

10.

Donnelly JP, Hanna M. Cardiac amyloidosis: an update on diagnosis and treatment. Cleve Clin J Med. 2017;84(12 Suppl 3):12–26. https://doi.org/10.3949/ccjm.84.s3.02] ([PMID: 29257735]).CrossRefPubMed

11.

González-López E, López-Sainz Á, Garcia-Pavia P. Diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and hope. Rev Esp Cardiol (Engl Ed). 2017;70(11):991–1004. https://doi.org/10.1016/j.rec.2017.05.036 ([PMID: 28870641]).CrossRef

12.

European Medicines Agency—Committee for Orphan Medicinal Products. Orphan maintanence assessment report for Vyndaqel: European medicines agency; 2020. Available from: URL: https://www.ema.europa.eu/en/documents/orphan-maintenance-report-post/vyndaqel-orphan-maintenance-assessment-report-post-authorisation_en.pdf.

13.

Castaño A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015;20(2):163–78. https://doi.org/10.1007/s10741-014-9462-7 ([PMID: 25408161]).CrossRefPubMedPubMedCentral

14.

Grogan M, Dispenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart. 2017;103(14):1065–72. https://doi.org/10.1136/heartjnl-2016-310704 ([PMID: 28456755]).CrossRefPubMed

15.

Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol. 2018;33(5):571–9. https://doi.org/10.1097/HCO.0000000000000547 ([PMID: 30015648]).CrossRefPubMed

16.

Ruberg FL, Maurer MS, Judge DP, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164(2):222-228.e1. https://doi.org/10.1016/j.ahj.2012.04.015 ([PMID: 22877808]).CrossRefPubMed

17.

Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357–77. https://doi.org/10.1161/circulationaha.116.024438 ([PMID: 28373528]).CrossRefPubMedPubMedCentral

18.

Winburn I, Ishii T, Sumikawa T, Togo K, Yasunaga H. Estimating the prevalence of transthyretin amyloid cardiomyopathy in a large in-hospital database in Japan. Cardiol Ther. 2019;8(2):297–316. https://doi.org/10.1007/s40119-019-0142-5 ([PMID: 31376091]).CrossRefPubMedPubMedCentral

19.

Ladefoged B, Dybro A, Povlsen JA, Vase H, Clemmensen TS, Poulsen SH. Diagnostic delay in wild-type transthyretin cardiac amyloidosis—a clinical challenge. Int J Cardiol. 2020;304:138–43. https://doi.org/10.1016/j.ijcard.2019.12.063 ([PMID: 32033783]).CrossRefPubMed

20.

Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232–9. https://doi.org/10.1080/07853890701842988] ([PMID: 18382889]).CrossRefPubMed

21.

Halatchev IG, Zheng J, Ou J. Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies. J Thorac Dis. 2018;10(3):21034–45. https://doi.org/10.2137/jtd.2018.03.134 ([PMID: 29707360]).CrossRef

22.

Chacko L, Martone R, Bandera F, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J. 2020. https://doi.org/10.1093/eurheartj/ehz905 ([PMID: 31950987]).CrossRefPubMed

23.

Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014–20. https://doi.org/10.1016/j.jacc.2016.06.033 ([PMID: 27585505]).CrossRefPubMed

24.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097 ([PMID: 19621072]).CrossRefPubMedPubMedCentral

25.

Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84. https://doi.org/10.1136/jech.52.6.377 ([PMID: 9764259]).CrossRefPubMedPubMedCentral

26.

Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443–57. https://doi.org/10.1002/sim.2380 ([PMID: 16345038]).CrossRefPubMed

27.

Sterne JAC, Egger M, Moher D, Boutron I. Chapter 10: Addressing reporting biases. In: biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS. Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 2017.

28.

Funnel plot tool; 2018. Available from: URL: https://improvement.nhs.uk/resources/funnel-plot-tool/.

29.

Haidich AB. Meta-analysis in medical research. Hippokratia. 2010;14(Suppl 1):29–37 ([PMID: 21487488]).PubMedPubMedCentral

30.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. https://doi.org/10.1016/0197-2456(86)90046-2 ([PMID: 3802833]).CrossRefPubMed

31.

Miller JJ. The inverse of the freeman—Tukey Double arcsine transformation. Am Stat. 1978a;32(4):138. https://doi.org/10.1080/00031305.1978.10479283].CrossRef

32.

Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950;21(4):607–11.CrossRef

33.

Miller GR. The current status of theory and research in interpersonal communication. Human Comm Res. 1978b;4(2):164–78. https://doi.org/10.1111/j.1468-2958.1978.tb00606.x.CrossRef

34.

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 2019.

35.

Kamangar F. Confounding variables in epidemiologic studies: basics and beyond. Arch Iran Med. 2012;15(8):508–16 ([PMID: 22827790]).PubMed

36.

Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS Med. 2008;5(3):e67. https://doi.org/10.1371/journal.pmed.0050067 ([PMID: 18336067]).CrossRefPubMedPubMedCentral

37.

Viechtbauer W. Conducting meta-analyses in R with the metafor Package. J Stat Soft. 2010. https://doi.org/10.1837/jss.v036.i03.CrossRef

38.

RStudio: Integrated Development Environment for R. Boston, MA: RStudio Team; 2020. Available from: URL: http://www.rstudio.com/.

39.

JASP (Version 0.12.2)[Computer software] JASP Team; 2020. Available from: URL: https://jasp-stats.org/.

40.

Clemmensen TS, Eiskjær H, Mølgaard H, et al. Abnormal coronary flow velocity reserve and decreased myocardial contractile reserve are main factors in relation to physical exercise capacity in cardiac amyloidosis. J Am Soc Echocardiogr. 2018;31(1):71–8. https://doi.org/10.1016/j.echo.2017.09.007 ([PMID: 29111120]).CrossRefPubMed

41.

Sanchis K, Cariou E, Colombat M, et al. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality. Amyloid. 2019;26(3):128–38. https://doi.org/10.1080/13506129.2019.1620724 ([PMID: 31172799]).CrossRefPubMed

42.

Longhi S, Quarta CC, Milandri A, et al. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid. 2015;22(3):147–55. https://doi.org/10.3109/13506129.2015.1028616 ([PMID: 25997105]).CrossRefPubMed

43.

de Siepen F, Hein S, Prestel S, et al. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy? Clin Res Cardiol. 2019;108(12):1324–30. https://doi.org/10.1007/s00392-019-01467-1 ([PMID: 30953182]).CrossRef

44.

Nakagawa M, Sekijima Y, Yazaki M, et al. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid. 2016;23(1):58–63. https://doi.org/10.3109/13506129.2015.1135792 ([PMID: 26852880]).CrossRefPubMed

45.

Connors LH, Doros G, Sam F, Badiee A, Seldin DC, Skinner M. Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy. Amyloid. 2011;18(Suppl 1):157–9. https://doi.org/10.3109/13506129.2011.574354059 ([PMID: 21838471]).CrossRefPubMedPubMedCentral

46.

Ueda M, Horibata Y, Shono M, et al. Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol. 2011;24(12):1533–44. https://doi.org/10.1038/modpathol.2011.117] ([PMID: 21822203]).CrossRefPubMed

47.

Takashio S, Yamamuro M, Izumiya Y, et al. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail. 2018;5(1):27–35. https://doi.org/10.1002/ehf2.12203] ([PMID: 28869340]).CrossRefPubMed

48.

Perfetto F, Bergesio F, Grifoni E, et al. Different NT-proBNP circulating levels for different types of cardiac amyloidosis. J Cardiovasc Med (Hagerstown). 2016;17(11):810–7. https://doi.org/10.2459/JCM.0000000000000349 ([PMID: 26765991]).CrossRef

49.

Burrage M, Korczyk D, Mollee P. 1955 First Australian registry of patients with wild-type cardiac amyloidosis (ATTRwt): Queensland experience. Eur Heart J. 2017. https://doi.org/10.1093/eurheartj/ehx502.1955.CrossRef

50.

Rubin J, Alvarez J, Teruya S, et al. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? Amyloid. 2017;24(4):226–30. https://doi.org/10.1080/13506129.2017.1375908 ([PMID: 28906148]).CrossRefPubMed

51.

Damy T, Jaccard A, Guellich A, et al. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis. Amyloid. 2016;23(3):194–202. https://doi.org/10.1080/13506129.2016.1221815 ([PMID: 27647161]).CrossRefPubMed

52.

Binder C, Duca F, Stelzer PD, et al. Mechanisms of heart failure in transthyretin vs. light chain amyloidosis. Eur Heart J Cardiovasc Imaging. 2019;20(5):512–24. https://doi.org/10.1093/ehjci/jey225 ([PMID: 30649240]).CrossRefPubMed

53.

Bartier S, Bodez D, Kharoubi M, et al. Pharyngo-laryngeal involvement in systemic amyloidosis with cardiac involvement: a prospective observational study. Amyloid. 2019;26(4):216–24. https://doi.org/10.1080/13506129.2019.1646639 ([PMID: 31364411]).CrossRefPubMed

54.

Kim HM, Sohn D-W, Paeng JC. Prevalence of positive 99 mTc-DPD scintigraphy as an Indicator of the prevalence of wild-type transthyretin amyloidosis in the elderly. Int Heart J. 2019;60(3):643–7. https://doi.org/10.1536/ihj.18-345 ([PMID: 31019172]).CrossRefPubMed

55.

Benson MD, Dasgupta NR, Rissing SM, Smith J, Feigenbaum H. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Amyloid. 2017;24(4):219–25. https://doi.org/10.1080/13506129.2017.1374946 ([PMID: 28906150]).CrossRefPubMed

56.

Wilson WM, Gonzales M, Voukelatos J, Morton JB. Senile cardiac amyloidosis. Intern Med J. 2010;40(6):468–9. https://doi.org/10.1111/j.1445-5994.2010.02250.x ([PMID: 20636833]).CrossRefPubMed

57.

Sperry BW, Vranian MN, Hachamovitch R, et al. Subtype-specific interactions and prognosis in cardiac amyloidosis. J Am Heart Assoc. 2016;5(3):e002877. https://doi.org/10.1161/JAHA.115.002877 ([PMID: 27013539]).CrossRefPubMedPubMedCentral

58.

Lo Presti S, Horvath SA, Mihos CG, Rajadhyaksha C, McCloskey V, Santana O. Transthyretin cardiac amyloidosis as diagnosed by 99mTc-PYP scanning in patients with acute heart failure and preserved ejection fraction. Crit Pathw Cardiol. 2019;18(4):195–9. https://doi.org/10.1097/HPC.0000000000000183 ([PMID: 31725511]).CrossRefPubMed

59.

Sultan MB, Gundapaneni B, Schumacher J, Schwartz JH. Treatment with tafamidis slows disease progression in early-stage transthyretin cardiomyopathy. Clin Med Insights Cardiol. 2017;11:1179546817730322. https://doi.org/10.1177/1179546817730322] ([PMID: 28951660]).CrossRefPubMedPubMedCentral

60.

Hanson JLS, Arvanitis M, Koch CM, et al. Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin. Circ Heart Fail. 2018;11(2):e004000. https://doi.org/10.1161/circheartfailure.117.004000 ([PMID: 29449366]).CrossRefPubMedPubMedCentral

61.

Escher F, Senoner M, Doerler J, et al. When and how do patients with cardiac amyloidosis die? Clin Res Cardiol. 2020;109(1):78–88. https://doi.org/10.1007/s00392-019-01490-2 ([PMID: 31134330]).CrossRefPubMed

62.

Shiozaki T, Sato N, Hayashi T, Kobayashi K, Asamura H. Wild-type ATTR amyloidosis may be associated with unexpected death among the elderly. Leg Med (Tokyo). 2019;41:101634. https://doi.org/10.1016/j.legalmed.2019.101634 ([PMID: 31731233]).CrossRef

63.

González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–94. https://doi.org/10.1093/eurheartj/ehv338 ([PMID: 26224076]).CrossRefPubMed

64.

Grogan M, Scott C, Lin G, et al. Rapid Fire Abstract session: new insights in cardiomyopthies, 436 Wild type transthyretin cardiac amyloidosis: clinical characteristics, echocardiographic findings, and predictors of outcome. Eur Heart J Cardiovasc Imaging. 2015;16(suppl 2):S51–3. https://doi.org/10.1093/ehjci/jev254.CrossRef

65.

Kristen AV, Haufe S, Schonland SO, et al. Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol. 2013;164(2):179–84. https://doi.org/10.1016/j.ijcard.2011.06.123 ([PMID: 21764155]).CrossRefPubMed

66.

Siepen FAD, Bauer R, Voss A, et al. Predictors of survival stratification in patients with wild-type cardiac amyloidosis. Clin Res Cardiol. 2018;107(2):158–69. https://doi.org/10.1007/s00392-017-1167-1 ([PMID: 28956153]).CrossRefPubMed

67.

Yamamoto Y, Onoguchi M, Haramoto M, et al. Novel method for quantitative evaluation of cardiac amyloidosis using (201)TlCl and (99m)Tc-PYP SPECT. Ann Nucl Med. 2012;26(8):634–43. https://doi.org/10.1007/s12149-012-0627-y ([PMID: 22777859]).CrossRefPubMed

68.

Bhupathy P, Haines CD, Leinwand LA. Influence of sex hormones and phytoestrogens on heart disease in men and women. Womens Health (Lond Engl). 2010;6(1):77–95. https://doi.org/10.2217/whe.09.80 ([PMID: 20088732]).CrossRef

69.

Bruno M, Castaño A, Burton A, Grodin JL. Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges. Heart Fail Rev. 2020. https://doi.org/10.1007/s10741-020-10010-8 ([PMID: 32794090]).CrossRefPubMedCentral

70.

Eastwood J-A, Doering LV. Gender differences in coronary artery disease. J Cardiovasc Nurs. 2005;20(5):340–51. https://doi.org/10.1097/00005082-200509000-00008 (quiz 352–3, PMID: 16141779).CrossRefPubMed

71.

Gold LD, Krumholz HM. Gender differences in treatment of heart failure and acute myocardial infarction: a question of quality or epidemiology? Cardiol Rev. 2006;14(4):180–6. https://doi.org/10.1097/01.crd.0000194093.53005.f0 ([PMID: 16788330]).CrossRefPubMed

72.

Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12. https://doi.org/10.1161/circulationaha.116.021612 ([PMID: 27143678]).CrossRefPubMed

73.

Westermark P, Westermark GT, Suhr OB, Berg S. Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis. Ups J Med Sci. 2014;119(3):223–8. https://doi.org/10.3109/03009734.2014.895786 (PMID: 24620715).CrossRefPubMedPubMedCentral

74.

Kristen AV, Bauer R, de Siepen F, et al. Wild-type transthyretin amyloidosis in female patients. Orphanet J Rare Dis. 2015. https://doi.org/10.1186/1750-1172-10-S1-O9.CrossRefPubMedCentral

Title: Estimating the Gender Distribution of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis
Authors: Florint Kroi
Nils Fischer
Ana Gezin
Mahmoud Hashim
Mark Hermannes Rozenbaum
Publication date: 01-06-2021
Publisher: Springer Healthcare
Keywords: Autopsy
Cardiomyopathy
Amyloidosis
Published in: Cardiology and Therapy / Issue 1/2021
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI: https://doi.org/10.1007/s40119-020-00205-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Preoperative, Multidisciplinary Clinical Optimization of Patients with Severely Depressed Left Ventricular Ejection Fraction Who Are Undergoing Coronary Artery Bypass Grafting

Contemporary Strategies to Manage High Blood Pressure in Patients with Coexistent Resistant Hypertension and Heart Failure With Reduced Ejection Fraction

Point-of-Care Testing for D-Dimer in the Diagnosis of Venous Thromboembolism in Primary Care: A Narrative Review

Coronary Artery Bypass: Review of Surgical Techniques and Impact on Long-Term Revascularization Outcomes

Distal Transradial Access for Coronary Angiography and Interventions in Everyday Practice: Data From the TRIANGLE Registry (TwitteR Initiated registry for coronary ANgiography in Germany via distaL radial accEss)

Impact of Coronary Stent Architecture on Clinical Outcomes: Do Minor Changes in Stent Architecture Really Matter?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials